TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proprietary Information - Exploratory (Non-Confirmatory) Trial
Brief Summary: The purpose of this study is to demonstrate an improvement in physical functional recovery, following administration of Drug for 24 weeks, in patients who have recently experienced a hip fracture. This study will also evaluate the safety and tolerability of Drug.

This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Plus Program | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Plus Program; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: MK0677; Assigned to Arm(s): N/A
C: Arm Label: Home-based physical exercise; Type: EXPERIMENTAL; Interventions: Other: Home-based physical exercise intervention | Arm Label: Control Group Usual Care; Type: OTHER; Interventions: Other: Control Group Usual Care | Intervention Type: OTHER; Name: Home-based physical exercise intervention; Assigned to Arm(s): Home-based physical exercise | Intervention Type: OTHER; Name: Control Group Usual Care; Assigned to Arm(s): Control Group Usual Care
D: Arm Label: physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: physiotherapy | Arm Label: conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: physiotherapy; Assigned to Arm(s): physiotherapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cranberry and Prevention of UTI A Comprehensive Approach
Brief Summary: This study will determine whether cranberry juice is effective in reducing recurrent urinary tract infections (UTIs) in women who have had a UTI within the past year.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4
B: Arm Label: Cranberry powder capsules; Type: EXPERIMENTAL; Interventions: Drug: Cranberry powder capsules | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo powder capsules | Intervention Type: DRUG; Name: Cranberry powder capsules; Assigned to Arm(s): Cranberry powder capsules | Intervention Type: DRUG; Name: Placebo powder capsules; Assigned to Arm(s): Placebo capsules
C: Intervention Type: DRUG; Name: Cranberries - Vaccinium macrocarpon; Assigned to Arm(s): N/A
D: Arm Label: Cranberry-lingonberry juice; Type: EXPERIMENTAL; Interventions: Other: Cranberry-lingonberry juice | Arm Label: Placebo juice; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo juice | Intervention Type: OTHER; Name: Cranberry-lingonberry juice; Assigned to Arm(s): Cranberry-lingonberry juice | Intervention Type: OTHER; Name: Placebo juice; Assigned to Arm(s): Placebo juice

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cranberry and Prevention of UTI A Comprehensive Approach
Brief Summary: This study will determine whether cranberry juice is effective in reducing recurrent urinary tract infections (UTIs) in women who have had a UTI within the past year.


Options:
A: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
B: Arm Label: Optimal dose; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Arm Label: Control dose; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cranberry extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry extract; Assigned to Arm(s): Control dose, Optimal dose
C: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cranberry and Prevention of UTI A Comprehensive Approach
Brief Summary: This study will determine whether cranberry juice is effective in reducing recurrent urinary tract infections (UTIs) in women who have had a UTI within the past year.


Options:
A: Arm Label: cranberry juice; Type: ACTIVE_COMPARATOR; Interventions: Other: cranberry juice | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo beverage | Intervention Type: OTHER; Name: cranberry juice; Assigned to Arm(s): cranberry juice | Intervention Type: OTHER; Name: placebo beverage; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Cranberry juice; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cranberry juice cocktail | Intervention Type: DRUG; Name: Cranberry juice cocktail; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6-59 Months of Age
Brief Summary: The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.


Options:
A: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Liquid CAIV-T; Assigned to Arm(s): N/A
C: Arm Label: TIV-adj; Type: EXPERIMENTAL; Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine | Arm Label: Flu-control; Type: ACTIVE_COMPARATOR; Interventions: Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine | Arm Label: Non-flu Control; Type: SHAM_COMPARATOR; Interventions: Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine | Intervention Type: BIOLOGICAL; Name: Adjuvanted trivalent inactivated subunit influenza vaccine; Assigned to Arm(s): TIV-adj | Intervention Type: BIOLOGICAL; Name: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine; Assigned to Arm(s): Flu-control | Intervention Type: BIOLOGICAL; Name: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine; Assigned to Arm(s): Non-flu Control
D: Arm Label: Influenza vaccine LAIV; Type: EXPERIMENTAL; Interventions: Biological: Trivalent Inactivated Vaccine | Arm Label: Influenza vaccine TIV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Live Attenuated Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: Trivalent Inactivated Vaccine; Assigned to Arm(s): Influenza vaccine LAIV | Intervention Type: BIOLOGICAL; Name: Live Attenuated Influenza Vaccine; Assigned to Arm(s): Influenza vaccine TIV

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial of Short Course Rifampin Versus INH for LTBI in Jail
Brief Summary: The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. One group of volunteers will take INH two times a week for 9 months, and the other group will take rifampin daily for 4 months. Medication will be administered in jail and at the San Francisco TB Clinic if the volunteer is released from jail prior to completing the study. Participants will be seen daily for 4 months (rifampin group), and 2 times a week for 9 months (INH group) for directly observed therapy. Study procedures will include 5 symptom review visits and blood samples for lab testing. Follow-up will continue for each subject for five years after enrollment into the study.


Options:
A: Arm Label: HIVneg/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVneg/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Arm Label: HIVpos/INH; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid (INH), Drug: Trimethoprim/Sulfamethoxazole (TMP/SMX) | Arm Label: HIVpos/PL; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isoniazid Placebo (PL) | Intervention Type: DRUG; Name: Isoniazid (INH); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Trimethoprim/Sulfamethoxazole (TMP/SMX); Assigned to Arm(s): HIVneg/INH, HIVpos/INH | Intervention Type: DRUG; Name: Isoniazid Placebo (PL); Assigned to Arm(s): HIVneg/PL, HIVpos/PL
B: Arm Label: Isoniazid preventive therapy; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Cotrimoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Cotrimoxazole, Other: placebo | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: DRUG; Name: Cotrimoxazole; Assigned to Arm(s): Isoniazid preventive therapy, Placebo | Intervention Type: DRUG; Name: isoniazid; Assigned to Arm(s): Isoniazid preventive therapy | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifampin | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): A
D: Intervention Type: DRUG; Name: I ( isoniazid), II (isoniazid + rifampin ); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Computerized brief intervention (5As); Type: EXPERIMENTAL; Interventions: Behavioral: Computer-delivered brief intervention (5As) | Arm Label: Contingency Management Alone; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: Combined Brief Intervention and CM; Type: EXPERIMENTAL; Interventions: Behavioral: Computer-delivered brief intervention (5As), Behavioral: Contingency Management | Intervention Type: BEHAVIORAL; Name: Computer-delivered brief intervention (5As); Assigned to Arm(s): Combined Brief Intervention and CM, Computerized brief intervention (5As) | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Combined Brief Intervention and CM, Contingency Management Alone
C: Arm Label: Group commitment contracts; Type: EXPERIMENTAL; Interventions: Behavioral: Group commitment contract, Behavioral: Smoking cessation education and counseling | Arm Label: Education and counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation education and counseling | Intervention Type: BEHAVIORAL; Name: Group commitment contract; Assigned to Arm(s): Group commitment contracts | Intervention Type: BEHAVIORAL; Name: Smoking cessation education and counseling; Assigned to Arm(s): Education and counseling, Group commitment contracts
D: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Lung Age; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age | Arm Label: Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management | Arm Label: Lung age + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age + Contingency Management | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Lung age; Assigned to Arm(s): Lung Age | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Contingency Management | Intervention Type: BEHAVIORAL; Name: Lung age + Contingency Management; Assigned to Arm(s): Lung age + Contingency Management

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Arm Label: Original contingent vouchers schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Voucher-based incentives | Arm Label: Revised contingent vouchers schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Voucher-based incentives | Arm Label: Non-contingent vouchers schedule; Type: SHAM_COMPARATOR; Interventions: Behavioral: Voucher-based incentives | Intervention Type: BEHAVIORAL; Name: Voucher-based incentives; Assigned to Arm(s): Non-contingent vouchers schedule, Original contingent vouchers schedule, Revised contingent vouchers schedule
B: Arm Label: Traditional Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Traditional Contingency Management | Arm Label: Early Enhanced Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Early Enhanced Contingency Management | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Treatment | Intervention Type: BEHAVIORAL; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BEHAVIORAL; Name: Traditional Contingency Management; Assigned to Arm(s): Traditional Contingency Management | Intervention Type: BEHAVIORAL; Name: Early Enhanced Contingency Management; Assigned to Arm(s): Early Enhanced Contingency Management
C: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: E-cigarette free access; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette free access | Arm Label: E-cigarette/NRT/Zyban/Chantix Choice; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette/NRT/Zyban/Chantix Choice | Arm Label: Outcome Incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Outcome Incentive arm | Arm Label: Loss framing incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: E-cigarette free access; Assigned to Arm(s): E-cigarette free access | Intervention Type: BEHAVIORAL; Name: E-cigarette/NRT/Zyban/Chantix Choice; Assigned to Arm(s): E-cigarette/NRT/Zyban/Chantix Choice | Intervention Type: BEHAVIORAL; Name: Outcome Incentive arm; Assigned to Arm(s): Outcome Incentive arm | Intervention Type: BEHAVIORAL; Name: Loss framing incentive arm; Assigned to Arm(s): Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Wellness counseling | Intervention Type: BEHAVIORAL; Name: Wellness counseling; Assigned to Arm(s): Lifestyle intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Employee wellness programme | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Comparator (Once off educational session and educational materials) | Intervention Type: BEHAVIORAL; Name: Employee wellness programme; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Comparator (Once off educational session and educational materials); Assigned to Arm(s): Control group
C: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
D: Arm Label: Control-group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control-group | Arm Label: Intervention-group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention-group | Intervention Type: BEHAVIORAL; Name: Intervention-group; Assigned to Arm(s): Intervention-group | Intervention Type: BEHAVIORAL; Name: Control-group; Assigned to Arm(s): Control-group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proactive Care; Type: EXPERIMENTAL; Interventions: Behavioral: Proactive Outreach with choice of telephone or in-person smoking cessation services | Intervention Type: BEHAVIORAL; Name: Proactive Outreach with choice of telephone or in-person smoking cessation services; Assigned to Arm(s): Proactive Care
B: Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: placebo | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Life Style Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: IVR intervention | Arm Label: Life Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: IVR control | Intervention Type: BEHAVIORAL; Name: IVR intervention; Assigned to Arm(s): Life Style Counseling | Intervention Type: BEHAVIORAL; Name: IVR control; Assigned to Arm(s): Life Counseling

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP Trial: COlchicine for Recurrent Pericarditis
Brief Summary: The purpose of the study is to determine whether colchicine is safe and effective in the treatment and prevention of recurrent pericarditis (first episode).


Options:
A: Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine (for 6 months) | Intervention Type: DRUG; Name: Colchicine (for 6 months); Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: High Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: High Dose Colchicine (4.8 mg total dose) | Arm Label: Low Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Low Dose Colchicine (1.8mg total dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Control | Intervention Type: DRUG; Name: High Dose Colchicine (4.8 mg total dose); Assigned to Arm(s): High Dose Colchicine | Intervention Type: DRUG; Name: Low Dose Colchicine (1.8mg total dose); Assigned to Arm(s): Low Dose Colchicine | Intervention Type: OTHER; Name: Placebo Control; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The COPPS Trial: COlchicine for the Prevention of Postpericardiotomy Syndrome
Brief Summary: The purpose of the study is to determine whether colchicine is safe and effective in the prevention of the postpericardiotomy syndrome.


Options:
A: Arm Label: High Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: High Dose Colchicine (4.8 mg total dose) | Arm Label: Low Dose Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Low Dose Colchicine (1.8mg total dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Control | Intervention Type: DRUG; Name: High Dose Colchicine (4.8 mg total dose); Assigned to Arm(s): High Dose Colchicine | Intervention Type: DRUG; Name: Low Dose Colchicine (1.8mg total dose); Assigned to Arm(s): Low Dose Colchicine | Intervention Type: OTHER; Name: Placebo Control; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colchicine | Intervention Type: DRUG; Name: Colchicine; Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Colchicine; Type: EXPERIMENTAL; Interventions: Drug: Colchicine (for 6 months) | Intervention Type: DRUG; Name: Colchicine (for 6 months); Assigned to Arm(s): Colchicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Colchicine (for 1 month); Assigned to Arm(s): N/A

Answer: D